ADAM10: A new player in breast cancer progression?

British Journal of Cancer

Volumn 113, Issue 6, 2015, Pages 945-951

  Mullooly, Maeve ^a,b   McGowan, Patricia M ^a,b   Kennedy, Susan A ^c   Madden, Stephen F ^d   Crown, John ^b,d   O'Donovan, Norma ^d   Duffy, Michael J ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; ESTROGEN RECEPTOR; GI 254023X; MESSENGER RNA; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; 3-(FORMYLHYDROXYAMINO)-2-(3-PHENYL-1-PROPYL)BUTANOIC ACID (2,2-DIMETHYL-1-METHYLCARBAMOYL-1-PROPYL)AMIDE; ADAM PROTEIN; ADAM10 PROTEIN, HUMAN; DIPEPTIDE; HYDROXAMIC ACID; MEMBRANE PROTEIN; SECRETASE; TUMOR PROTEIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BT20 CELL LINE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CELL COUNT; CELL MIGRATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MDA MB 231 CELL LINE; MDA MB 453 CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; CELL MOTION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; CELL COUNT; CELL LINE, TUMOR; CELL MOVEMENT; DIPEPTIDES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84941878286     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.288     Document Type: Article

References (29)

1. Arima T, Enokida H, Kubo H, Kagara I, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Idesako T, Nishiyama K, Nakagawa M (2007) Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Sci 98: 1720-1726.
2. Blobel CP (2005) ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6: 32-43.
3. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J (2003) TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22: 1114-1124.
4. Bozhulak EC, Weinmaster G (2009) Selective use of ADAM10 and ADAM17 in activation of Notch 1 signaling. Mol Cell Biol 29: 5679-5695.
5. Duffy MJ, McGowan PM, Crown J (2012) Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 131: 2471-2477.
6. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM (2009) Role of ADAMs in cancer formation and progression. Clin Cancer Res 15: 1140-1144.
7. Duffy MJ, Lynn DJ, Lloyd AT, O'Shea CM (2003) The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb Haemostat 89: 622-631.
8. Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A (2014) ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget 5: 6633-6646.
9. Franovic A, Robert I, Smith K, Kurban G, Pause A, Gunaratnam L, Lee S (2006) Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res 66: 8083-8090.
10. Gaida MM, Haag N, Günther F, Tschaharganeh DF, Schirmacher P, Friess H, Giese NA, Schmidt J, Wente MN (2010) Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med 26: 281-288.
11. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lübke T, Lena Illert A, von Figura K, Saftig P (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11: 2615-2624.
12. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186-1195.
13. Kenny PA, Bissell MJ (2007) Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117: 337-345.
14. Lee SB, Schramme A, Doberstein K, Dummer R, Abdel-Bakky MS, Keller S, Altevogt P, Oh ST, Reichrath J, Oxmann D, Pfeilschifter J, Mihic-Probst D, Gutwein P (2010) ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol 130: 763-773.
15. Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM, Leesnitzer MA, Becherer JD (2005) Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 8: 161-171.
16. Madden SF, Clarke C, Gaule P, Aherne ST, O'Donovan N, Clynes M, Crown J, Gallagher WM (2013) BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 15: R52.
17. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P (2005a) ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and b-catenin translocation. Proc Natl Acad Sci USA 102: 9182-9187.
18. Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P, Reiss K (2005b) L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 25: 9040-9053.
19. McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ (2013) ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol 24: 362-369.
20. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N, Duffy MJ (2007) ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 13: 2335-2343.
21. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V, Altevogt P (2001) Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155: 661-673.
22. Moss ML, Stoeck A, Yan W, Dempsey PJ (2008) ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 9: 2-8.
23. Murai T, Miyauchi T, Yanagida T, Sako Y (2006) Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem J 395: 65-71.
24. Murphy G (2008) The ADAMs: Signalling scissors in the tumour microenvironment. Nat Rev Cancer 9: 929-941.
25. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P (2005) ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 24: 742-752.
26. Sahin U, Blobel CP (2007) Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett 581: 41-44.
27. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769-779.
28. Solanas G, Cortina C, Servillano M, Batlle E (2011) Cleavage of E-cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling. Nat Cell Biol 13: 1100-1107.
29. Weber S, Niessen MT, Prox J, Lüllmann-Rauch R, Schmitz A, Schwanbeck R, Blobel CP, Jorissen E, de Strooper B, Niessen CM, Saftig P (2011) The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development 138: 495-505.